GlaxoSmithKline

News
GSK’s monthly HIV treatment breakthrough

GSK’s monthly HIV treatment breakthrough

GlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping closer to potentially changing lives of patients living with

R&D
GSK signs $300m R&D deal with 23andMe

GSK signs $300m R&D deal with 23andMe

GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information.